Eli Lilly and Company (NYSE:LLY) 6th Evercore ISI HealthCONx Conference November 28, 2023 3:50 PM ET Company Participants Dan Skovronsky - EVP, Chief Scientific and Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Michael DiFiore - Evercore ISI Umer Raffat Pleasure to have management team from Eli Lilly. There's a ton to go through. But Dan, I'll turn it over to you and what's on top of your mind, and we'll jump right into it. Dan Skovronsky Yes. No. Thanks for hosting us here. It's b ...

Eli Lilly and Company (NYSE:LLY) UBS Biopharma 2023 Conference November 8, 2023 3:00 PM ET Company Participants Patrik Jonsson - President, Lilly Immunology Conference Call Participants Trung Huynh - UBS Trung Huynh Okay. We're at the hour now. My name is Trung Huynh. I'm the U.S. pharma analyst here at UBS. Thank you, everyone, for joining in the room and also online. It's my pleasure today to host Eli Lilly, and we've got Patrik Jonsson, the President of Lilly Immunology. But upon Mike Mason's retirement, ...

Eli Lilly and Co (NYSE:LLY) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Joe Fletcher - SVP, IR David Ricks - Chairman, CEO & President Anat Ashkenazi - EVP & CFO Daniel Skovronsky - EVP, Chief Scientific & Medical Officer and President Michael Mason - EVP & President of Lilly Diabetes Anne White - EVP & President, Lilly Neuroscience Lilly Research Laboratories Ilya Yuffa - EVP of Eli Lilly and Company and President of Lilly International Conference Call Participants Tim ...

Q3 2023 Earnings Call ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_963a774122a012d792c54cd851551a8b.html ...

Eli Lilly and Co (NYSE:LLY) Q2 2023 Earnings Conference Call August 8, 2023 9:00 AM ET Company Participants Joe Fletcher - VP, IR David Ricks - Chairman, CEO & President Anat Ashkenazi - EVP & CFO Daniel Skovronsky - EVP, Chief Scientific & Medical Officer and President Anne White - EVP & President, Lilly Neuroscience Lilly Research Laboratories Jake Van Naarden - EVP, CEO, Loxo Oncology & President, Lilly Oncology Patrik Jonsson - EVP, Chief Customer Officer, President, Lilly USA & Lilly Immunology Michael ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip ...

Eli Lilly and Company (NYSE:LLY) 2023 AAIC Lilly Alzheimer’s Disease Update Conference July 17, 2023 1:00 PM ET Company Participants Lauren Zierke - Executive Director of IR Daniel Skovronsky - Chief Scientific and Medical Officer Anne White - President, Lilly Neuroscience Mark Mintun - Group Vice President of Neuroscience Research and Development; President, Avid Radiopharmaceuticals John Sims - Head of Clinical Development for Donanemab Conference Call Participants Tim Anderson - Wolfe Research Alec Stran ...

Eli Lilly and Company (NYSE:LLY) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 4:20 PM ET Company Participants Anat Ashkenazi - Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's kick off the afternoon session here. I hope everyone enjoyed the lunchtime discussion and has had a positive and productive morning so far. My name is Chris Shibutani. I'm a member of the research team. We are thrilled to be able to present Lilly a ...